Verdiva Bio develops targeted therapies that enhance metabolic function and weight management in patients with obesity and cardiometabolic diseases. Their treatments focus on improving insulin sensitivity and reducing inflammation, leading to better health outcomes for affected individuals.
Funding
$410M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
FCGAFounders
Product
Problem
Obesity and cardiometabolic disorders represent a significant and growing global health challenge. Current therapeutic options often fail to provide patient-friendly solutions that effectively address the underlying metabolic dysfunction and related complications.
Solution
Verdiva Bio is developing a portfolio of next-generation therapies designed to improve outcomes for individuals with obesity, cardiometabolic disorders, and associated complications. Their approach leverages emerging science in gut-brain biology to create differentiated medicines that target unmet needs in this space. The company's lead therapy, VRB-101, is an oral GLP-1 peptide agonist in clinical development, demonstrating potential for compelling efficacy with a convenient once-weekly dosing regimen. Verdiva Bio is also advancing multiple amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs, all aimed at achieving enhanced efficacy, improved tolerability, and healthier weight loss profiles. These therapies are being developed both as monotherapies and in combination to address the complex needs of patients with cardiometabolic diseases.
Target Audience
The primary target audience includes individuals with obesity, cardiometabolic disorders, and related complications, as well as healthcare providers specializing in endocrinology, cardiology, and metabolic health.
Features
- VRB-101: An oral, once-weekly GLP-1 receptor agonist in Phase 1 clinical development for obesity.
- VRB-103: An oral, once-weekly, dual amylin and calcitonin receptor agonist (DACRA) in preclinical development for obesity, designed for monotherapy or combination with oral GLP-1 therapy.
- VRB-102: An injectable, once-weekly, dual amylin and calcitonin receptor agonist (DACRA) in preclinical development for obesity, designed for monotherapy or combination with VRB-101.
- Oral and subcutaneous amylin agonists with the potential for enhanced efficacy and improved tolerability.
- Combination therapies of GLP-1 and amylin agonists for synergistic effects on weight loss and metabolic function.